Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group.

Roberto Luksch, Giovanni Grignani, Paolo D'Angelo, Arcangelo Prete, Nadia Puma, Marta Podda, Michele Casanova, Andrea Ferrari, Carlo Morosi, Franca Fagioli, Massimo Aglietta, Stefano Ferrari, Piero Picci, Maura Massimino

Research output: Contribution to journalArticle

Abstract

The aim was to assess the activity of cisplatin (CDDP) in Ewing sarcoma (ES). The study consisted of front-line window therapy with CDDP 120 mg/sqm every 3 weeks for two courses in children and young adults with primary disseminated ES. Response was assessed using the Response Evaluation Criteria in Solid Tumours criteria, and Simon's two-stage design was applied. Twelve consecutive patients were enrolled in stage 1. Only one objective response was observed. Since the target response rate was not achieved, accrual was stopped and CDDP as a single agent in ES was judged unworthy of further assessment.
Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalPediatric Blood and Cancer
Volume64
Issue number12
DOIs
Publication statusPublished - Jun 14 2017

Fingerprint

Ewing's Sarcoma
Sarcoma
Cisplatin
Young Adult
Therapeutics

Keywords

  • Ewing sarcoma
  • cisplatin
  • metastatic

Cite this

Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. / Luksch, Roberto; Grignani, Giovanni; D'Angelo, Paolo; Prete, Arcangelo; Puma, Nadia; Podda, Marta; Casanova, Michele; Ferrari, Andrea; Morosi, Carlo; Fagioli, Franca; Aglietta, Massimo; Ferrari, Stefano; Picci, Piero; Massimino, Maura.

In: Pediatric Blood and Cancer, Vol. 64, No. 12, 14.06.2017, p. 1-4.

Research output: Contribution to journalArticle

@article{47b86d204f8e4ea5bf80c828c883f39a,
title = "Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group.",
abstract = "The aim was to assess the activity of cisplatin (CDDP) in Ewing sarcoma (ES). The study consisted of front-line window therapy with CDDP 120 mg/sqm every 3 weeks for two courses in children and young adults with primary disseminated ES. Response was assessed using the Response Evaluation Criteria in Solid Tumours criteria, and Simon's two-stage design was applied. Twelve consecutive patients were enrolled in stage 1. Only one objective response was observed. Since the target response rate was not achieved, accrual was stopped and CDDP as a single agent in ES was judged unworthy of further assessment.",
keywords = "Ewing sarcoma, cisplatin, metastatic",
author = "Roberto Luksch and Giovanni Grignani and Paolo D'Angelo and Arcangelo Prete and Nadia Puma and Marta Podda and Michele Casanova and Andrea Ferrari and Carlo Morosi and Franca Fagioli and Massimo Aglietta and Stefano Ferrari and Piero Picci and Maura Massimino",
year = "2017",
month = "6",
day = "14",
doi = "10.1002/pbc.26650",
language = "English",
volume = "64",
pages = "1--4",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Front-line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group.

AU - Luksch, Roberto

AU - Grignani, Giovanni

AU - D'Angelo, Paolo

AU - Prete, Arcangelo

AU - Puma, Nadia

AU - Podda, Marta

AU - Casanova, Michele

AU - Ferrari, Andrea

AU - Morosi, Carlo

AU - Fagioli, Franca

AU - Aglietta, Massimo

AU - Ferrari, Stefano

AU - Picci, Piero

AU - Massimino, Maura

PY - 2017/6/14

Y1 - 2017/6/14

N2 - The aim was to assess the activity of cisplatin (CDDP) in Ewing sarcoma (ES). The study consisted of front-line window therapy with CDDP 120 mg/sqm every 3 weeks for two courses in children and young adults with primary disseminated ES. Response was assessed using the Response Evaluation Criteria in Solid Tumours criteria, and Simon's two-stage design was applied. Twelve consecutive patients were enrolled in stage 1. Only one objective response was observed. Since the target response rate was not achieved, accrual was stopped and CDDP as a single agent in ES was judged unworthy of further assessment.

AB - The aim was to assess the activity of cisplatin (CDDP) in Ewing sarcoma (ES). The study consisted of front-line window therapy with CDDP 120 mg/sqm every 3 weeks for two courses in children and young adults with primary disseminated ES. Response was assessed using the Response Evaluation Criteria in Solid Tumours criteria, and Simon's two-stage design was applied. Twelve consecutive patients were enrolled in stage 1. Only one objective response was observed. Since the target response rate was not achieved, accrual was stopped and CDDP as a single agent in ES was judged unworthy of further assessment.

KW - Ewing sarcoma

KW - cisplatin

KW - metastatic

U2 - 10.1002/pbc.26650

DO - 10.1002/pbc.26650

M3 - Article

VL - 64

SP - 1

EP - 4

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 12

ER -